|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar
|
|
2
|
D’Amico AV, Whittington R, Malkowicz SB,
et al: Clinical utility of the percentage of positive prostate
biopsies in defining biochemical outcome after radical
prostatectomy for patients with clinically localized prostate
cancer. J Clin Oncol. 18:1164–1172. 2000.
|
|
3
|
Wilt TJ, Brawer MK, Jones KM, et al:
Radical prostatectomy versus observation for localized prostate
cancer. N Engl J Med. 367:203–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rider JR, Sandin F, Andren O, Wiklund P,
Hugosson J and Stattin P: Long-term outcomes among non-curatively
treated men according to prostate cancer risk category in a
nationwide, population-based study. Eur Urol. 63:88–96. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA: SEER
Cancer Statistics Review, 1975–2010. National Cancer Institute;
Bethesda: http://seer.cancer.gov/csr/1975_2010/.
2013
|
|
6
|
Loblaw DA, Virgo KS, Nam R, et al: Initial
hormonal management of androgen-sensitive metastatic, recurrent, or
progressive prostate cancer: 2006 update of an American Society of
Clinical Oncology practice guideline. J Clin Oncol. 25:1596–1605.
2007. View Article : Google Scholar
|
|
7
|
Mickisch GH, Garin A, van Poppel H, de
Prijck L and Sylvester R: Radical nephrectomy plus
interferon-alfa-based immunotherapy compared with interferon alfa
alone in meta-static renal-cell carcinoma: a randomised trial.
Lancet. 358:966–970. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glehen O, Mohamed F and Gilly FN:
Peritoneal carcinomatosis from digestive tract cancer: new
management by cytoreductive surgery and intraperitoneal
chemohyperthermia. Lancet Oncol. 5:219–228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Early Breast Cancer Trialists’
Collaborative Group. Polychemotherapy for early breast cancer: an
overview of the randomised trials. Lancet. 352:930–942. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bristow RE, Tomacruz RS, Armstrong DK,
Trimble EL and Montz FJ: Survival effect of maximal cytoreductive
surgery for advanced ovarian carcinoma during the platinum era: a
meta-analysis. J Clin Oncol. 20:1248–1259. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schroder FH, Kurth KH, Fossa SD, et al:
Early versus delayed endocrine treatment of N1–3 M0 prostate cancer
without local treatment of the primary tumor: results of European
Organisation for the Research and Treatment of Cancer 30846 - a
phase III study. J Urol. 172:923–927. 2004.PubMed/NCBI
|
|
12
|
Messing EM, Manola J, Yao J, et al:
Immediate versus deferred androgen deprivation treatment in
patients with node-positive prostate cancer after radical
prostatectomy and pelvic lymphadenectomy. Lancet Oncol. 7:472–479.
2006. View Article : Google Scholar
|
|
13
|
Engel J, Bastian PJ, Baur H, et al:
Survival benefit of radical prostatectomy in lymph node-positive
patients with prostate cancer. Eur Urol. 57:754–761. 2010.
View Article : Google Scholar
|
|
14
|
Ghavamian R, Bergstralh EJ, Blute ML,
Slezak J and Zincke H: Radical retropubic prostatectomy plus
orchiectomy versus orchiectomy alone for pTxN+ prostate
cancer: a matched comparison. J Urol. 161:1223–1228. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ward JF, Slezak JM, Blute ML, Bergstralh
EJ and Zincke H: Radical prostatectomy for clinically advanced
(cT3) prostate cancer since the advent of prostate-specific antigen
testing: 15-year outcome. BJU Int. 95:751–756. 2005.PubMed/NCBI
|
|
16
|
Swanson G, Thompson I, Basler J and
Crawford ED: Metastatic prostate cancer-does treatment of the
primary tumor matter? J Urol. 176:1292–1298. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Thompson IM, Tangen C, Basler J and
Crawford ED: Impact of previous local treatment for prostate cancer
on subsequent metastatic disease. J Urol. 168:1008–1012. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Swanson GP, Riggs M and Earle J: Failure
after primary radiation or surgery for prostate cancer: differences
in response to androgen ablation. J Urol. 172:525–528. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kantoff PW, Higano CS, Shore ND, et al:
Sipuleucel-T immunotherapy for castration-resistant prostate
cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shao YH, Kim S, Moore DF, et al:
Cancer-specific survival after metastasis following primary radical
prostatectomy compared with radiation therapy in prostate cancer
patients: results of a population-based, propensity score-matched
analysis. Eur Urol. 65:693–700. 2014. View Article : Google Scholar
|
|
21
|
Kadmon D, Heston WD and Fair WR: Treatment
of a metastatic prostate derived tumor with surgery and
chemotherapy. J Urol. 127:1238–1242. 1982.PubMed/NCBI
|
|
22
|
Henry JM and Isaacs JT: Relationship
between tumor size and the curability of metastatic prostatic
cancer by surgery alone or in combination with adjuvant
chemotherapy. J Urol. 139:1119–1123. 1988.PubMed/NCBI
|
|
23
|
Culp SH, Schellhammer PF and Williams MB:
Might men diagnosed with metastatic prostate cancer benefit from
definitive treatment of the primary tumor? A SEER-based study. Eur
Urol. 65:1058–1066. 2014. View Article : Google Scholar
|
|
24
|
Heidenreich A, Thissen AK, Piper C,
Pfister D and Porres D: Cytoreductive radical prostatectomy (CRP)
in patients with prostate cancer (PCA) and low-volume osseous
metastases. Proc ASCO. 32:abs. 272. 2014.PubMed/NCBI
|
|
25
|
Suardi N, Gandaglia G, Gallina A, et al:
Long-term outcomes of salvage lymph node dissection for clinically
recurrent prostate cancer: results of a single-institution series
with a minimum follow-up of 5 years. Eur Urol. Feb 18–2014.(Epub
ahead of print).
|
|
26
|
Berges RR, Vukanovic J, Epstein JI, et al:
Implication of cell kinetic changes during the progression of human
prostatic cancer. Clin Cancer Res. 1:473–480. 1995.PubMed/NCBI
|
|
27
|
Kim MY, Oskarsson T, Acharyya S, et al:
Tumor self-seeding by circulating cancer cells. Cell.
139:1315–1326. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Goldkorn A, Ely B, Quinn DI, et al:
Circulating tumor cell counts are prognostic of overall survival in
SWOG S0421: a phase III trial of docetaxel with or without
atrasentan for metastatic castration-resistant prostate cancer. J
Clin Oncol. 32:1136–1142. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Crook JM, Malone S, Perry G, et al:
Twenty-four-month post-radiation prostate biopsies are strongly
predictive of 7-year disease-free survival. Cancer. 115:673–679.
2009.PubMed/NCBI
|
|
31
|
Tzelepi V, Efstathiou E, Wen S, et al:
Persistent, biologically meaningful prostate cancer after 1 year of
androgen ablation and docetaxel treatment. J Clin Oncol.
29:2574–2581. 2011.PubMed/NCBI
|
|
32
|
Negri-Cesi P and Motta M: Androgen
metabolism in the human prostatic cancer cell line LNCaP. J Steroid
Biochem Mol Biol. 51:89–96. 1994. View Article : Google Scholar
|
|
33
|
Mostaghel EA, Page ST, Lin DW, et al:
Intraprostatic androgens and androgen-regulated gene expression
persist after testosterone suppression: therapeutic implications
for castration-resistant prostate cancer. Cancer Res. 67:5033–5041.
2007. View Article : Google Scholar
|
|
34
|
Mottet N, Bellmunt J, Bolla M, et al: EAU
guidelines on prostate cancer. Part II: treatment of advanced,
relapsing, and castration-resistant prostate cancer. Eur Urol.
59:572–583. 2011. View Article : Google Scholar
|
|
35
|
Ingels A, de la Taille A and Ploussard G:
Radical prostatectomy as primary treatment of high-risk prostate
cancer. Curr Urol Rep. 13:179–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gandaglia G, Abdollah F, Hu J, et al: Is
robot-assisted radical prostatectomy safe in men with high-risk
prostate cancer? Assessment of perioperative outcomes, positive
surgical margins, and use of additional cancer treatments. J
Endourol. Mar 24–2014.(Epub ahead of print).
|
|
37
|
Gandaglia G, Sun M, Trinh QD, et al:
Survival benefit of definitive therapy in patients with clinically
advanced prostate cancer: estimations of the number needed to treat
based on competing-risks analysis. BJU Int. Jan 27–2014.(Epub ahead
of print).
|
|
38
|
Berglund RK, Jones JS, Ulchaker JC, et al:
Radical prostatectomy as primary treatment modality for locally
advanced prostate cancer: a prospective analysis. Urology.
67:1253–1256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Loeb S, Smith ND, Roehl KA and Catalona
WJ: Intermediate-term potency, continence, and survival outcomes of
radical prostatectomy for clinically high-risk or locally advanced
prostate cancer. Urology. 69:1170–1175. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kundu SD, Roehl KA, Eggener SE, Antenor
JA, Han M and Catalona WJ: Potency, continence and complications in
3,477 consecutive radical retropubic prostatectomies. J Urol.
172:2227–2231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gontero P, Marchioro G, Pisani R, et al:
Is radical prostatectomy feasible in all cases of locally advanced
non-bone metastatic prostate cancer? Results of a
single-institution study. Eur Urol. 51:922–930. 2007. View Article : Google Scholar
|
|
42
|
Novara G, Ficarra V, D’Elia C, Secco S,
Cavalleri S and Artibani W: Prospective evaluation with
standardised criteria for postoperative complications after
robotic-assisted laparoscopic radical prostatectomy. Eur Urol.
57:363–370. 2010. View Article : Google Scholar
|
|
43
|
Agarwal PK, Sammon J, Bhandari A, et al:
Safety profile of robot-assisted radical prostatectomy: a
standardized report of complications in 3317 patients. Eur Urol.
59:684–698. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yuh B, Artibani W, Heidenreich A, et al:
The role of robot-assisted radical prostatectomy and pelvic lymph
node dissection in the management of high-risk prostate cancer: a
systematic review. Eur Urol. 65:918–927. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Oderda M, Joniau S, Spahn M and Gontero P:
Debulking surgery in the setting of very high-risk prostate cancer
scenarios. BJU Int. 110:E192–E198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gotto GT, Yunis LH, Vora K, Eastham JA,
Scardino PT and Rabbani F: Impact of prior prostate radiation on
complications after radical prostatectomy. J Urol. 184:136–142.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chade DC, Eastham J, Graefen M, et al:
Cancer control and functional outcomes of salvage radical
prostatectomy for radiation-recurrent prostate cancer: a systematic
review of the literature. Eur Urol. 61:961–971. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Haffner MC, Mosbruger T, Esopi DM, et al:
Tracking the clonal origin of lethal prostate cancer. J Clin
Invest. 123:4918–4922. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
49
|
Connolly SS, Cathcart PJ, Gilmore P, et
al: Robotic radical prostatectomy as the initial step in multimodal
therapy for men with high-risk localised prostate cancer: initial
experience of 160 men. BJU Int. 109:752–759. 2012. View Article : Google Scholar
|
|
50
|
Jung JH, Seo JW, Lim MS, et al: Extended
pelvic lymph node dissection including internal iliac packet should
be performed during robot-assisted laparoscopic radical
prostatectomy for high-risk prostate cancer. J Laparoendosc Adv
Surg Tech A. 22:785–790. 2012. View Article : Google Scholar
|
|
51
|
Lavery HJ, Nabizada-Pace F, Carlucci JR,
Brajtbord JS and Samadi DB: Nerve-sparing robotic prostatectomy in
preoperatively high-risk patients is safe and efficacious. Urol
Oncol. 30:26–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ou YC, Yang CK, Wang J, et al: The
trifecta outcome in 300 consecutive cases of robotic-assisted
laparoscopic radical prostatectomy according to D’Amico risk
criteria. Eur J Surg Oncol. 39:107–113. 2013.PubMed/NCBI
|
|
53
|
Rogers CG, Sammon JD, Sukumar S, Diaz M,
Peabody J and Menon M: Robot assisted radical prostatectomy for
elderly patients with high risk prostate cancer. Urol Oncol.
31:193–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sagalovich D, Calaway A, Srivastava A,
Sooriakumaran P and Tewari AK: Assessment of required nodal yield
in a high risk cohort undergoing extended pelvic lymphadenectomy in
robotic-assisted radical prostatectomy and its impact on functional
outcomes. BJU Int. 111:85–94. 2013. View Article : Google Scholar
|
|
55
|
Yuh BE, Ruel NH, Mejia R, Wilson CM and
Wilson TG: Robotic extended pelvic lymphadenectomy for
intermediate- and high-risk prostate cancer. Eur Urol.
61:1004–1010. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zugor V, Labanaris AP, Bauer RM and Witt
JH: Surgical and oncological outcomes in patients with a
preoperative PSA value <4 ng/ml undergoing robot-assisted
radical prostatectomy. Anticancer Res. 32:2079–2083. 2012.
|
|
57
|
Hsu CY, Joniau S, Oyen R, Roskams T and
Van Poppel H: Outcome of surgery for clinical unilateral T3a
prostate cancer: a single-institution experience. Eur Urol.
51:121–129. 2007. View Article : Google Scholar
|
|
58
|
Freedland SJ, Partin AW, Humphreys EB,
Mangold LA and Walsh PC: Radical prostatectomy for clinical stage
T3a disease. Cancer. 109:1273–1278. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Carver BS, Bianco FJ Jr, Scardino PT and
Eastham JA: Long-term outcome following radical prostatectomy in
men with clinical stage T3 prostate cancer. J Urol. 176:564–568.
2006. View Article : Google Scholar : PubMed/NCBI
|
